Navigation Links
Common Preterm Labor Drug Has More Side Effects Than Alternative,,Finds Study from Packard Children's Hospital and Stanford

STANFORD, Calif.--(BUSINESS WIRE)--Jun 29, 2007 - The drug most commonly used to arrest preterm labor, magnesium sulfate, is more likely than another common treatment to cause mild to serious side effects in pregnant women, according to a study from researchers at Lucile Packard Children's Hospital and Stanford University School of Medicine. Their findings suggest that, since the effectiveness of the two drugs appears similar, physicians should consider side effects more strongly when choosing which drug to prescribe.

Newborns whose mothers had received magnesium sulfate were also more likely to be admitted to the neonatal intensive care unit than those whose mothers had received the alternative treatment, although the data do not offer an explanation for this finding and more research needs to be conducted to rule out other causes. What is clear is that currently available treatments for preterm labor are far from perfect.

"There is no free lunch with any of these drugs," said Deirdre Lyell, MD, a specialist in high-risk obstetrics at the hospital's Johnson Center for Pregnancy and Newborn Services. "But magnesium sulfate has some particularly unpleasant side effects, including vomiting, lethargy and blurry vision. The alternative treatment, nifedipine, often leaves women feeling better."

Side effects are particularly important for women struggling with the risk of premature birth and the rapid medical decisions that might need to be made about the care of their newborn. Lyell, assistant professor of obstetrics and gynecology at the medical school, and Yasser El-Sayed, MD, associate professor of obstetrics and gynecology at the medical school, are the lead and senior authors respectively of the research, which will be published in the July issue of Obstetrics & Gynecology. The study is the largest multicenter trial that randomized the use of the preterm labor drugs to compare outcome.


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
3. Blood Levels of Paliperidone Extended-Release Tablets are Not Increased by Common Antidepressant
4. Researchers Discover a Common Variation in a Gene Segment that Increases the Risk for Prostate Cancer
5. Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually
6. One-Third of Patients Discontinue Common Breast Cancer Therapy
7. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
8. Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies
9. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
10. New Quality Control Systems for Every Laboratory Application
11. Immunoassay Systems - Your Laboratory Workhorse
Post Your Comments:
(Date:8/28/2014)... SALT LAKE CITY , Aug. 28, 2014 /PRNewswire-iReach/ ... in 2000 by service academy graduates, has published a ... its concentrated, three-day Leadership Excellence Course . In ... the  Leadership Excellence Course to Albuquerque , ... Tucson . Photo - http://photos.prnewswire.com/prnh/20140828/140814 ...
(Date:8/28/2014)... 28, 2014 The new ... Market (products, applications, techniques, end users and Geography) ... Forecast, 2013 - 2020," indicates that the global ... 2020 registering a CAGR of 9.8% from 2014 ... and cost effectiveness over alternative diagnostic techniques are ...
(Date:8/28/2014)... Aug. 28, 2014   Venaxis, Inc.  (Nasdaq:  APPY), ... obtaining FDA clearance for and commercializing its CE Marked ... aiding in identifying children, adolescent, and young adult patients ... for appendicitis, today announced it will present at three ... Annual Global Investment Conference being held in ...
Breaking Medicine Technology:Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3
... 2010 Kensey Nash Corporation (Nasdaq: KNSY ... in November.   Michael Celano, Kensey Nash,s ... the Oppenheimer 21st Annual Healthcare Conference at the Waldorf ... p.m. (ET).  To hear the live webcast of the ...
... (Nasdaq: SLTM ), a global leader in the ... ended September 30, 2010. Revenue for the third quarter was ... as compared to the third quarter 2009 revenue of $17.8 ... by a year-over-year 40% increase in sales of treatment tips ...
Cached Medicine Technology:Solta Medical Reports Third Quarter 2010 Results 2Solta Medical Reports Third Quarter 2010 Results 3Solta Medical Reports Third Quarter 2010 Results 4Solta Medical Reports Third Quarter 2010 Results 5Solta Medical Reports Third Quarter 2010 Results 6Solta Medical Reports Third Quarter 2010 Results 7Solta Medical Reports Third Quarter 2010 Results 8
(Date:8/28/2014)... Solid-head power toothbrushes retain less bacteria compared ... University of Texas Health Science Center at Houston ... study are published in the August issue of ... professor at the UTHealth School of Dentistry, Donna ... were lower in the solid-head toothbrush group than ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 ISI ... management solutions, will be sponsoring the 2014 Presidio ... annual event allows Presidio leadership to engage with ... year. Specifically, they will be rolling out objectives ... , While at the event, ISI will be ...
(Date:8/28/2014)... A candidate Ebola vaccine could be given to healthy ... early as September, as part of an series of ... disease that has killed more than 1,400 people in ... of this candidate vaccine, being co-developed by the US ... be accelerated with funding from an international consortium in ...
(Date:8/28/2014)... Initial human testing of an investigational vaccine to prevent ... National Institute of Allergy and Infectious Diseases (NIAID), part ... trial will begin initial human testing of a vaccine ... the experimental vaccine,s safety and ability to generate an ... place at the NIH Clinical Center in Bethesda, Maryland. ...
(Date:8/28/2014)... People aged 70 and over who identify themselves as ... where they perceive they have lower value than younger ... University of Kent, titled ,Being old and ill, across ... subjective health, used data from the European Social Survey. ... asked to self-rate their health., The researchers found that ...
Breaking Medicine News(10 mins):Health News:UTHealth researchers find up to 3,000 times the bacterial growth on hollow-head toothbrushes 2Health News:ISI Telemanagement Solutions, Inc. to Sponsor 2014 Presidio Exchange 2Health News:Ebola vaccine trials fast-tracked by international consortium 2Health News:Ebola vaccine trials fast-tracked by international consortium 3Health News:Ebola vaccine trials fast-tracked by international consortium 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5
... today announced their plans to expand their online video ... overwhelming success achieved by the website since its inception ... library has been visited by physicians from 64 different ... from repeat visits and the average length of stay ...
... Recent Developments at Major Patenting Authorities WorldwidePHILADELPHIA and LONDON, ... Thomson Reuters today released its 2009 Patent Focus ... Intellectual Asset Management magazine, and published in the ... , this report explores recent activities at each of ...
... SEATTLE, Feb. 17 Cell Therapeutics, Inc. (Nasdaq and ... a press release in Italy in response to information ... CTI,s business operations and financial condition, which was also ... February 17, 2009, the Borsa Italiana has confirmed that ...
... 17 The civil rights movement gained a ... of Representatives voted Feb. 17 to recognize the ... by American Life League Associate group North Dakota ... of The Personhood of Children Act (House Resolution ...
... Consumers who purchased raw milk from the Swiss Villa ... after Feb. 9 are advised to discard it immediately ... Secretary Dennis Wolff said today. Raw milk has not ... a result of the potential contamination, but if people ...
... Shenghuo,Pharmaceutical Holdings, Inc. (NYSE Alternext US: KUN) ("China ... 10, 2009, it received a,deficiency letter from the ... the,"Exchange") stating that the Company was not in ... standards due to the Company,s failure to,hold an ...
Cached Medicine News:Health News:Physicians online library is a worldwide hit 2Health News:Physicians online library is a worldwide hit 3Health News:Thomson Reuters Releases 2009 Patent Focus Report 2Health News:Cell Therapeutics to Resume Trading on MTA and NASDAQ 2Health News:North Dakota Personhood Bill Passes State House 51-41 2Health News:Consumer Advisory: Agriculture Department Warns of Tainted Raw Milk Sold By Dauphin County Dairy 2Health News:China Shenghuo Receives Notice from NYSE Alternext US Regarding Listing Standards 2Health News:China Shenghuo Receives Notice from NYSE Alternext US Regarding Listing Standards 3
... ROM Elbow Orthosis features aluminum cuffs that ... arm. To ensure proper joint alignment, unique ... and distal adjustments to cuff position. Cuffs ... is necessary for use with contractures.,The hinge ...
... Brace is designed to handle post-op elbow ... The Bledsoe Extender Arm Brace should be ... of the elbow is desired. In most ... be formed, fitted and adjusted in 5 ...
... This controlled stretch ankle support helps reduce ... of motion. It is easy to apply ... its slim design fits easily into shoes. ... the ankle, and provide side-to-side support and stability. ...
... ankle support provides excellent com-pression and ... motion. The anatomically sculpted visco-elastic ... weakened or injured soft tissues under ... to apply - slips on like ...
Medicine Products: